Tandem Diabetes Care, Inc. Increases Its Line of Credit With Capital Royalty Partners II, L.P. to $80 Million

Tandem Diabetes Care, Inc.

Represented Tandem Diabetes Care, Inc. (NSDQ:TNDM) in its Third Amendment to its Amended and Restated Term Loan Agreement with Capital Royalty Partners II L.P. and its affiliate funds. Under the Term Loan Agreement, Tandem has aggregate borrowings outstanding of $30 million and, pursuant to the Third Amendment, Tandem may borrow up to an additional $50 million.

Tandem, based in San Diego, California, is a medical device company with an innovative, user-centric and integrated approach to the design, development and commercialization of products for people with diabetes who use insulin. Among other products, Tandem manufactures and sells the t:slim G4™ Insulin Pump, the first CGM-enabled pump with touch-screen simplicity.

The Newport Beach-based team representing Tandem included Bruce Feuchter and Chris Ivey.